【摘要】：中藥是我國(guó)傳統(tǒng)文化中的瑰寶,是千百年醫(yī)療實(shí)踐的結(jié)晶。中藥是最具我國(guó)民族特色和獨(dú)特優(yōu)勢(shì)的產(chǎn)品,也是我國(guó)最有希望獲得國(guó)際競(jìng)爭(zhēng)優(yōu)勢(shì)的領(lǐng)域。近年來(lái),由于中藥市場(chǎng)尤其是中藥市場(chǎng)面臨著國(guó)際競(jìng)爭(zhēng)國(guó)內(nèi)化、國(guó)內(nèi)競(jìng)爭(zhēng)國(guó)際化的趨勢(shì),我國(guó)中藥企業(yè)既面臨著機(jī)會(huì),也面臨著挑戰(zhàn)。 一方面,隨著老齡化社會(huì)的到來(lái),以及人們對(duì)環(huán)保意識(shí)、健康意識(shí)不斷增強(qiáng),健康用藥已經(jīng)成為人們的共識(shí)。中藥作為“綠色”用藥,人們對(duì)中藥的消費(fèi)量不斷攀升。與此同時(shí),我國(guó)關(guān)于醫(yī)藥產(chǎn)業(yè)的“十二五”規(guī)劃中,首次將“支持中藥事業(yè)發(fā)展”單獨(dú)作為一節(jié)列示,為我國(guó)中藥行業(yè)的大力發(fā)展定下基調(diào)。根據(jù)“十二五”規(guī)劃,“十二五”期間我國(guó)中藥工業(yè)將保持年均12%以上的速度增長(zhǎng),到2015年中藥工業(yè)產(chǎn)值將達(dá)到5500億元。中藥產(chǎn)業(yè)不僅成為我國(guó)經(jīng)濟(jì)新的增長(zhǎng)點(diǎn),而且對(duì)我國(guó)產(chǎn)業(yè)結(jié)構(gòu)調(diào)整起著非常重要的作用。 另一方面,隨著世界經(jīng)濟(jì)的全球化和一體化,國(guó)外制藥企業(yè)也紛紛投入到天然植物藥市場(chǎng),這些企業(yè)憑借其在資金、技術(shù)等方面優(yōu)勢(shì),對(duì)我國(guó)中藥企業(yè)造成了極大的挑戰(zhàn)。 我國(guó)中藥企業(yè)如何去把握這種機(jī)會(huì),去迎接這種挑戰(zhàn)?重視和加大對(duì)中藥企業(yè)的財(cái)務(wù)競(jìng)爭(zhēng)力研究,增加企業(yè)的競(jìng)爭(zhēng)力,是中藥企業(yè)面對(duì)市場(chǎng)挑戰(zhàn)的主動(dòng)選擇。我們想通過“中藥上市公司財(cái)務(wù)競(jìng)爭(zhēng)力評(píng)價(jià)研究”課題的研究,一方面,構(gòu)建中藥企業(yè)財(cái)務(wù)競(jìng)爭(zhēng)力的評(píng)價(jià)體系,并以此評(píng)價(jià)體系,對(duì)我國(guó)中藥行業(yè)上市公司的財(cái)務(wù)競(jìng)爭(zhēng)力進(jìn)行評(píng)價(jià)和比較；另一方面,提出提升我國(guó)中藥企業(yè)財(cái)務(wù)競(jìng)爭(zhēng)力的對(duì)策,為我國(guó)中藥企業(yè)競(jìng)爭(zhēng)力的提升提供決策借鑒。因此,此項(xiàng)研究不僅具有重要的理論價(jià)值,也具有較強(qiáng)的實(shí)踐價(jià)值。
[Abstract]:Chinese medicine is the treasure of Chinese traditional culture and the crystallization of thousands of years of medical practice. Traditional Chinese medicine is the product with the most national characteristics and unique advantages of our country, and it is also the most promising field for our country to obtain the international competitive advantage. In recent years, the Chinese traditional medicine market, especially the traditional Chinese medicine market, is facing the trend of international competition and internationalization, so Chinese traditional medicine enterprises are faced with both opportunities and challenges. On the one hand, with the arrival of aging society, and people's awareness of environmental protection, health awareness has been strengthened, healthy drug use has become a common understanding. Chinese medicine as a "green" drug, people's consumption of traditional Chinese medicine is rising. At the same time, "supporting the development of traditional Chinese medicine" is listed as a section for the first time in the "12th Five-Year Plan" of China's pharmaceutical industry, which sets the tone for the vigorous development of Chinese traditional medicine industry. According to the 12th Five-Year Plan, China's traditional Chinese medicine industry will maintain an average annual growth rate of more than 12 percent during the 12th Five-Year Plan period, and the output value of the Chinese traditional medicine industry will reach 550 billion yuan by 2015. The traditional Chinese medicine industry not only becomes the new growth point of our country's economy, but also plays a very important role in the adjustment of our country's industrial structure. On the other hand, with the globalization and integration of the world economy, foreign pharmaceutical enterprises have also invested in the natural plant medicine market. With their advantages in capital, technology and other aspects, these enterprises have caused great challenges to Chinese traditional medicine enterprises. How do Chinese traditional medicine enterprises grasp this kind of opportunity to meet this kind of challenge? It is an active choice for traditional Chinese medicine enterprises to pay attention to and increase their financial competitiveness and increase their competitiveness in the face of market challenges. On the one hand, we want to construct the evaluation system of the financial competitiveness of traditional Chinese medicine enterprises through the research of "Evaluation Research on the Financial Competitiveness of listed Chinese Medicine companies". This paper evaluates and compares the financial competitiveness of listed companies in Chinese traditional Chinese medicine industry, and on the other hand, puts forward some countermeasures to enhance the financial competitiveness of Chinese traditional medicine enterprises, which provides a reference for the promotion of the competitiveness of Chinese traditional medicine enterprises. Therefore, this research not only has important theoretical value, but also has strong practical value.
【學(xué)位授予單位】：廣西師范大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2013
【分類號(hào)】：F275;F426.72

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 尹猛基;向希堯;;專利競(jìng)爭(zhēng)優(yōu)勢(shì)研究綜述[J];商業(yè)研究;2008年11期

2 朱開悉;財(cái)務(wù)管理目標(biāo)與企業(yè)財(cái)務(wù)核心能力[J];財(cái)經(jīng)論叢(浙江財(cái)經(jīng)學(xué)院學(xué)報(bào));2001年05期

3 郝成林;齊榮光;郭江山;;企業(yè)財(cái)務(wù)競(jìng)爭(zhēng)力研究[J];財(cái)會(huì)通訊(學(xué)術(shù)版);2006年03期

4 孫新憲;胡建琦;;財(cái)務(wù)核心能力研究[J];財(cái)會(huì)通訊(學(xué)術(shù)版);2006年12期

5 朱曉;;上市公司財(cái)務(wù)競(jìng)爭(zhēng)力研究與分析[J];財(cái)會(huì)通訊(學(xué)術(shù)版);2007年07期

6 張友棠;馮自欽;;三維財(cái)務(wù)競(jìng)爭(zhēng)力形成機(jī)理研究[J];財(cái)會(huì)通訊(綜合版);2008年08期

7 周海軍;曾理;;基于改進(jìn)DEA方法的企業(yè)財(cái)務(wù)競(jìng)爭(zhēng)力評(píng)價(jià)[J];財(cái)會(huì)通訊;2009年05期

8 郝成林;頊志芬;;財(cái)務(wù)競(jìng)爭(zhēng)力及其構(gòu)成要素解析[J];財(cái)會(huì)月刊;2006年08期

9 吳荷青;;財(cái)務(wù)競(jìng)爭(zhēng)力的熵權(quán)系數(shù)評(píng)價(jià)法[J];財(cái)政監(jiān)督;2008年20期

10 羅宏,陳燕;財(cái)務(wù)能力與企業(yè)核心能力的相關(guān)性[J];當(dāng)代財(cái)經(jīng);2003年12期

相關(guān)碩士學(xué)位論文 前10條

1 范麗芳;基于綜合指數(shù)法的上市公司財(cái)務(wù)競(jìng)爭(zhēng)力評(píng)價(jià)及應(yīng)用研究[D];天津財(cái)經(jīng)大學(xué);2011年

2 杜振波;山東省區(qū)域經(jīng)濟(jì)差異及其協(xié)調(diào)發(fā)展問題研究[D];山東大學(xué);2011年

3 余西平;JM公司財(cái)務(wù)核心競(jìng)爭(zhēng)力的評(píng)價(jià)研究[D];湖南大學(xué);2010年

4 王萌;上市公司財(cái)務(wù)競(jìng)爭(zhēng)力綜合分析與評(píng)價(jià)研究[D];北京郵電大學(xué);2012年

5 陳峰;推進(jìn)中藥產(chǎn)業(yè)成為我國(guó)戰(zhàn)略產(chǎn)業(yè)的研究[D];浙江大學(xué);2002年

6 肖峻;我國(guó)中藥企業(yè)核心能力評(píng)價(jià)[D];首都經(jīng)濟(jì)貿(mào)易大學(xué);2003年

7 馬�；�;我國(guó)中藥企業(yè)的專利保護(hù)研究[D];四川大學(xué);2003年

8 郝民;從同仁堂看中藥企業(yè)國(guó)際化經(jīng)營(yíng)[D];對(duì)外經(jīng)濟(jì)貿(mào)易大學(xué);2005年

9 朱劍飛;河南中藥企業(yè)競(jìng)爭(zhēng)力提升研究[D];鄭州大學(xué);2005年

10 崔鈞;從天士力集團(tuán)看中藥產(chǎn)業(yè)的國(guó)際營(yíng)銷[D];昆明理工大學(xué);2006年

，

本文編號(hào)：2153756